



(11) **EP 2 310 415 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07K 16/28^(2006.01) G01N 33/68^(2006.01)

(48) Corrigendum issued on:
22.11.2017 Bulletin 2017/47

(86) International application number:
PCT/US2009/002536

(45) Date of publication and mention
of the grant of the patent:
11.10.2017 Bulletin 2017/41

(87) International publication number:
WO 2009/131702 (29.10.2009 Gazette 2009/44)

(21) Application number: **09734929.4**

(22) Date of filing: **24.04.2009**

(54) **ANTIBODIES AGAINST FCRN AND USE THEREOF**

ANTIKÖRPER GEGEN FCRN UND DEREN VERWENDUNG

PROTÉINES DE LIAISON AU RÉCEPTEUR FC

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK TR

(30) Priority: **25.04.2008 US 48152 P**
28.04.2008 US 48500 P

(43) Date of publication of application:
20.04.2011 Bulletin 2011/16

(60) Divisional application:
17195757.4

(73) Proprietors:
• **Dyax Corp.**
Burlington, MA 01803 (US)
• **Biogen Hemophilia Inc.**
Waltham, MA 02451 (US)

(72) Inventors:
• **TENHOOR, Christopher**
Hopkinton
MA 01748 (US)
• **MURUGANANDAM, Arumugam**
Bangalore 560035 (IN)

- **LADNER, Robert, Charles**
Ijamsville
MD 21754 (US)
- **WOOD, Clive**
Boston, MA 02114 (US)
- **BITONTI, Alan, J.**
Acton
MA 01720 (US)
- **STATTEL, James**
Hagerstown
MD 21740 (US)
- **MCDONNELL, Kevin**
Waltham
MA 02451 (US)
- **LIU, Liming**
Upper Dublin
PA 19002 (US)
- **DUMONT, Jennifer**
Groton
MA 01450 (US)
- **SATO, Aaron**
Richmond
CA 94805 (US)

(74) Representative: **Carpmaels & Ransford LLP**
One Southampton Row
London WC1B 5HA (GB)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 310 415 B8

(56) References cited:

WO-A-2006/118772 WO-A-2007/087289
US-A1- 2007 092 507

- LIU LIMING ET AL: "Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade" JOURNAL OF IMMUNOLOGY, vol. 178, no. 8, April 2007 (2007-04), pages 5390-5398, XP009124948 ISSN: 0022-1767
- GETMAN KATE E ET AL: "Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions" JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 94, no. 4, 1 April 2005 (2005-04-01), pages 718-729, XP002417287 ISSN: 0022-3549
- LI NING ET AL: "Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases" JOURNAL OF CLINICAL INVESTIGATION, vol. 115, no. 12, December 2005 (2005-12), pages 3440-3450, XP009124853 ISSN: 0021-9738
- AKILESH SHREERAM ET AL: "The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease" JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 9, 1 May 2004 (2004-05-01), pages 1328-1333, XP002417288 ISSN: 0021-9738
- ROOPENIAN DERRY C ET AL: "FcRn: the neonatal Fc receptor comes of age" NATURE REVIEWS. IMMUNOLOGY, XX, XX, vol. 7, no. 9, 1 September 2007 (2007-09-01), pages 715-725, XP002510057 ISSN: 1474-1733
- LORIN ROSKOS ET AL: "Molecular Engineering II: Antibody Affinity", HANDBOOK OF THERAPEUTIC ANTIBODIES, WILEY-VCH, WEINHEIM, no. Part I, Chapter 7, 30 March 2007 (2007-03-30), XP007912251, ISBN: 978-3-527-31453-9 [retrieved on 2008-02-01]
- STEPHAN DUEBEL ED - STEFAN DÜBEL: "Handbook of Therapeutic Antibodies Chapter 6", 1 January 2007 (2007-01-01), HANDBOOK OF THERAPEUTIC ANTIBODIES, WILEY-VCH, WEINHEIM, PAGE(S) 119 - 144, XP007913671, ISBN: 978-3-527-31453-9